Depakene and Disseminated tuberculosis - a phase IV clinical study of FDA data

Summary:

We study 14,554 people who have side effects when taking Depakene. Disseminated tuberculosis is found, especially among people who are female, 60+ old, have been taking the drug for < 1 month, also take Allegra and have Glioblastoma multiforme.

The phase IV clinical study analyzes which people take Depakene and have Disseminated tuberculosis. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 21, 2023

14,554 people reported to have side effects when taking Depakene.
Among them, 3 people (0.02%) have Disseminated tuberculosis.

What is Depakene?

Depakene has active ingredients of valproic acid. It is used in epilepsy. Currently, eHealthMe is studying from 14,719 Depakene users.

What is Disseminated tuberculosis?

Disseminated tuberculosis is found to be associated with 683 drugs and 492 conditions by eHealthMe. Currently, we are studying 4,139 people who have Disseminated tuberculosis.

Number of Depakene and Disseminated tuberculosis reports submitted per year:

Could Depakene cause Disseminated tuberculosis?

Time on Depakene when people have Disseminated tuberculosis *:

Gender of people who have Disseminated tuberculosis when taking Depakene *:

female: 100 %
male: 0.0 %

Age of people who have Disseminated tuberculosis when taking Depakene *:

Common drugs people take besides Depakene *:

Common side effects people have besides Disseminated tuberculosis *:

Erythema Multiforme (a type of hypersensitivity reaction): 2 people, 66.67%
Visual Acuity Reduced (reduced clearness of vision): 1 person, 33.33%
Social Avoidant Behavior: 1 person, 33.33%
Scan Nos Brain Abnormal: 1 person, 33.33%
Motormental Retardation (a slowing-down of thought and a reduction of physical work): 1 person, 33.33%
Lymphopenia (an abnormally low level of lymphocytes in the blood): 1 person, 33.33%
Drowsiness: 1 person, 33.33%
Disturbance In Attention: 1 person, 33.33%
Diplopia (double vision): 1 person, 33.33%
Agitation (state of anxiety or nervous excitement): 1 person, 33.33%

Common conditions people have *:

Glioblastoma Multiforme (most common and deadliest of malignant primary brain tumours in adults): 2 people, 66.67%

* Approximation only. Some reports may have incomplete information.

Do you take Depakene and have Disseminated tuberculosis?

Check whether Disseminated tuberculosis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Gupta E, Kunjal R, Cury JD, "Severe hyponatremia due to valproic acid toxicity", Journal of clinical medicine research, 2015 Jan .
Hwabejire JO, Lu J, Liu B, Li Y, Halaweish I, Alam HB, "Valproic acid for the treatment of hemorrhagic shock: a dose-optimization study", journal of surgical research, 2014 Jan .

Related studies

Depakene side effects by duration, gender and age:

Depakene side effects (14,719 reports)

Disseminated tuberculosis treatments and more:

Disseminated tuberculosis (4,139 reports)

Common drugs associated with Disseminated tuberculosis:

All the drugs that are associated with Disseminated tuberculosis:

Disseminated tuberculosis (683 drugs)

Common conditions associated with Disseminated tuberculosis:

All the conditions that are associated with Disseminated tuberculosis:

Disseminated tuberculosis (492 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on valproic acid (the active ingredients of Depakene) and Depakene (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.